1005201-24-0

Basic information

• Product Name: 2-Methyl-5-[3-[4-(methylsulfinyl)phenyl]-5-benzofuranyl]-1,3,4-oxadiazole
• Synonyms: 2-Methyl-5-[3-[4-(methylsulfinyl)phenyl]-5-benzofuranyl]-1,3,4-oxadiazole;TCS 2002;1,3,4-Oxadiazole, 2-Methyl-5-[3-[4-(Methylsulfinyl)phenyl]-5-benzofuranyl]-;2-methyl-5-[3-(4-methylsulfinylphenyl)-1-benzofuran-5-yl]-1,3,4-oxadiazole
• CAS NO: 1005201-24-0
• Molecular Formula: C₁₈H₁₄N₂O₃S
• Molecular Weight: 338
• Mol File: 1005201-24-0.mol
• Article Data: 2

Chemical Properties

• Appearance: /
• Storage Temp.: Store at +4°C
• Solubility: <33.84mg/ml in DMSO; <8.46mg/ml in ethanol
• CAS DataBase Reference: 2-Methyl-5-[3-[4-(methylsulfinyl)phenyl]-5-benzofuranyl]-1,3,4-oxadiazole(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Methyl-5-[3-[4-(methylsulfinyl)phenyl]-5-benzofuranyl]-1,3,4-oxadiazole(1005201-24-0)
• EPA Substance Registry System: 2-Methyl-5-[3-[4-(methylsulfinyl)phenyl]-5-benzofuranyl]-1,3,4-oxadiazole(1005201-24-0)

Safety Data

• Hazardous Substances Data: 1005201-24-0(Hazardous Substances Data)

Usage

Uses

TCS 2002 is a Wnt/β-catenin signaling modulator, which is associated with diseases such as cancer and Alzheimer’s diasease.

Biological Activity

tcs 2002 is a potent inhibitor of gsk-3β with ic50 value of 35 nm [1].glycogen synthase kinase 3 (gsk-3) is a serine/threonine protein kinase and functions by phosphorylating a serine or threonine residue on its target protein. gsk3β plays an important role in neuronal cell development, energy metabolism and body pattern formation.tcs 2002 is a potent gsk -3β inhibitor with ic50 value of 35 nm. (s) -tcs 2002 and (r) -tcs 2002 inhibited gsk-3β with ic50 values of 34 and 140 nm, respectively. tcs 2002 exhibited good bioavailability (f=40%) and solubility (38 μg/ml). (s) -tcs 2002 showed no inhibitory activity against 12 tyrosine kinases and 10 serine/threonine kinases up to 10 μm, indicating that (s) -tcs 2002 was a highly selective gsk -3β inhibitor [1].in mice, cold water stress (cws) induced tau hyperphosphorylation at several gsk -3β directed sites such as s199, thr205, thr231 and ser396. (s) -tcs 2002 significantly inhibited tau phosphorylation by 35% [1].

references

[1]. saitoh m, kunitomo j, kimura e, et al. 2-{3-[4-(alkylsulfinyl)phenyl]-1-benzofuran-5-yl}-5-methyl-1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3beta with good brain permeability. j med chem, 2009, 52(20): 6270-6286.

Upstream product

• 1005201-23-9 2-methyl-5-{3-[4-(methylsulfanyl)phenyl]-1-benzofuran-5-yl}-1,3,4-oxadiazole 

Downstream Products

• 1005203-15-5 2-methyl-5-{3-[4-(methylsulfinyl)phenyl]-1-benzofuran-5-yl}-1,3,4-oxadiazole 
• 1005203-14-4 2-methyl-5-{3-[4-(methylsulfinyl)phenyl]-1-benzofuran-5-yl}-1,3,4-oxadiazole 
• 1191885-54-7 4-(2,4-dimethoxybenzyl)-3-methyl-5-{3-[4-(methylsulfinyl)phenyl]-1-benzofuran-5-yl}-4H-1,2,4-triazole 

Relevant articles and documents

GSK-3BETAINHIBITOR

For the purpose of providing a GSK-3β inhibitor containing an oxadiazole compound or a salt thereof or a prodrug thereof useful as an agent for the prophylaxis or treatment of a GSK-3β-related pathology or disease, the present invention provides a GSK-3β inhibitor containing a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof or a prodrug thereof.